- About Us
- Nano-Social Network
- Nano Consulting
- My Account
June 17th, 2007
Tempo Hurries To Target Nanoparticle Combo Drugs
Tempo Pharmaceuticals Inc. isn't wasting any time. Since its founding in late 2006, the Cambridge, Mass.-based company has raised Seed and Series A financings, licensed core technology, hired 15 employees, started partnership discussions and begun the process of translating its platform into a product fit for clinical trials.
Yet founder and CEO Alan Crane said the name Tempo refers not to the company's frenetic pace, but to the "temporal release" of multiple drugs from its Nanocell platform technology.
|Related News Press|
Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers
Argon is not the 'dope' for metallic hydrogen March 24th, 2017
Promising results obtained with a new electrocatalyst that reduces the need for platinum: Researchers from Aalto University have succeeded in manufacturing electrocatalysts used for storing electric energy with one-hundredth of the amount of platinum that is usually needed March 24th, 2017